Hippocrates Research Foundation
Informed Patient Series — Alzheimer's Disease, Booklet 3 of 3
Standard Alzheimer's medications — cholinesterase inhibitors and anti-amyloid antibodies — target only one or two pathways in a disease driven by at least fifteen. They modestly slow decline. They do not reverse it.
Yet reversal has been documented. Dr. Dale Bredesen's published case series demonstrate measurable cognitive improvement in patients with mild cognitive impairment and early Alzheimer's disease using comprehensive, multi-pathway protocols. The key insight is straightforward: if a disease has many contributing causes, effective treatment must address many causes simultaneously.
Booklet 1 in this series explained what Alzheimer's disease is and why it develops. Booklet 2 covered diagnostic testing — from standard imaging to advanced immune and metabolic panels. This booklet — Booklet 3 — presents the treatment interventions themselves: repurposed prescription drugs, targeted supplements, device-based therapies, dietary protocols, and lifestyle modifications that address the full spectrum of Alzheimer's pathophysiology.
Every intervention discussed here has published scientific evidence supporting its use. Some have large population studies; others have compelling mechanistic data and smaller clinical trials. We present them honestly — including what we still don't know — so that you and your physician can make informed decisions together.
No single intervention in this booklet is a cure. Combined into a personalized protocol, they represent the most comprehensive evidence-based approach currently available.
The interventions below are organized by category: repurposed drugs first, then supplements, device-based therapies, dietary and lifestyle protocols, and gut microbiome restoration. At the end, you will find a phased implementation timeline designed to introduce these interventions gradually and safely.
Do not attempt to start everything at once. Work with a physician experienced in integrative or functional medicine to prioritize interventions based on your individual test results (see Booklet 2) and implement them in a structured, stepwise fashion.
Repurposed drugs are medications originally approved for other conditions that show evidence of benefit in Alzheimer's disease. They have established safety profiles from years of clinical use, are generally affordable, and are available now — not in five years after a clinical trial concludes.
A landmark retrospective study of 7.23 million patient records published in Nature Aging (Fang et al., 2021) found that sildenafil use was associated with a 69% reduced risk of Alzheimer's diagnosis. The Cleveland Clinic research team used computational network medicine to screen 1,600 FDA-approved drugs, and sildenafil emerged as the top candidate. Laboratory validation confirmed that the drug increased neurite growth, reduced tau phosphorylation, and enhanced amyloid clearance markers in patient-derived neuronal cultures.
The mechanism is multifaceted. PDE5 inhibitors increase cerebral blood flow by enhancing nitric oxide signaling — directly addressing the 10–15% reduction in cerebral perfusion seen in mild cognitive impairment and the 40–50% reduction in late-stage Alzheimer's. They also cross the blood-brain barrier, activate CREB signaling (critical for memory consolidation), and reduce neuroinflammation.
Tadalafil has a longer half-life (17.5 hours versus 4 hours for sildenafil), allowing once-daily dosing and more consistent cerebral perfusion. It has not been studied as extensively for Alzheimer's specifically, partly because it remains under patent protection, reducing financial incentive for generic drug research. However, its pharmacological profile suggests it may be equally or more effective.
Typical dosing: Sildenafil 25–50 mg daily; Tadalafil 5–10 mg daily.
LDN at 1.5–4.5 mg (one-tenth of the standard dose for addiction) modulates the immune system through a paradoxical mechanism: brief opioid receptor blockade triggers an upregulation of endorphin production and shifts microglial cells from their pro-inflammatory M1 phenotype toward the neuroprotective M2 phenotype. In Alzheimer's, chronic microglial activation drives neuroinflammation and synaptic damage. LDN recalibrates this response.
LDN also upregulates opioid growth factor (OGF) signaling, which influences cell proliferation and immune regulation. Clinical experience in autoimmune and neuroinflammatory conditions demonstrates its safety and tolerability with minimal side effects (typically limited to vivid dreams during the first week of use).
Typical dosing: 1.5 mg at bedtime, titrating up to 4.5 mg over several weeks. Available through compounding pharmacies.
Metformin activates AMPK (AMP-activated protein kinase), the master metabolic sensor that stimulates autophagy — the cellular recycling process that clears damaged proteins including amyloid-beta and hyperphosphorylated tau. Multiple epidemiological studies demonstrate reduced Alzheimer's incidence in diabetic patients taking metformin compared to those on other glucose-lowering medications.
Beyond glucose regulation, metformin enhances mitochondrial function, reduces mTOR signaling (promoting cellular housekeeping over growth), and decreases neuroinflammation. It addresses the insulin resistance that characterizes what researchers increasingly call "type 3 diabetes" — the brain's inability to properly utilize glucose that drives energy crisis and clearance failure.
Typical dosing: 500–2,000 mg daily, titrated slowly to minimize gastrointestinal side effects. Extended-release formulation is better tolerated.
The brain becomes insulin resistant years before peripheral diabetes manifests. Intranasal delivery bypasses the blood-brain barrier via olfactory and trigeminal nerve pathways, delivering insulin directly to the central nervous system without causing systemic hypoglycemia.
The SNIFF trial (Study of Nasal Insulin to Fight Forgetfulness) demonstrated improved delayed memory in patients with mild cognitive impairment and early Alzheimer's, with effects visible on FDG-PET scans showing improved cerebral glucose metabolism. Intranasal insulin enhances synaptic plasticity, reduces tau phosphorylation, modulates inflammatory signaling, and improves cerebral blood flow regulation.
Typical dosing: 20–40 IU daily via nasal delivery device. Available through compounding pharmacies.
Rapamycin inhibits mTOR (mechanistic target of rapamycin), the nutrient-sensing pathway that when chronically activated suppresses autophagy. In Alzheimer's, impaired autophagy means the brain cannot efficiently clear damaged mitochondria, misfolded proteins, or amyloid aggregates. Intermittent rapamycin dosing restores autophagic function while minimizing immunosuppressive effects.
Animal studies demonstrate reduced amyloid plaque burden, decreased tau phosphorylation, improved cerebral blood flow, and restored blood-brain barrier integrity with intermittent rapamycin. Human longevity research using weekly low-dose rapamycin shows improved immune function — paradoxically enhancing rather than suppressing immunity when used intermittently.
Typical dosing: 1–6 mg weekly (pulsed dosing). Requires physician monitoring of lipids and blood counts.
Methylene blue is a unique compound that functions as an alternative electron carrier in the mitochondrial electron transport chain. When Complex I or Complex III are impaired — as occurs in Alzheimer's — methylene blue can shuttle electrons directly to Complex IV (cytochrome c oxidase), bypassing the damaged components and restoring ATP production.
Additionally, methylene blue inhibits tau aggregation, reduces amyloid-beta production, enhances autophagy, and has demonstrated neuroprotective effects in multiple animal models. Its ability to directly address the mitochondrial energy crisis — the core mechanism described in Booklet 1 — makes it mechanistically compelling.
Typical dosing: 0.5–1 mg/kg daily. Pharmaceutical grade (USP) required — not aquarium grade. Contraindicated with SSRI medications due to serotonin syndrome risk.
These tetracycline antibiotics have anti-amyloid properties independent of their antimicrobial effects. Both inhibit amyloid-beta aggregation, reduce matrix metalloproteinase (MMP) activity that damages the blood-brain barrier, and modulate microglial activation. Minocycline is particularly effective at crossing the blood-brain barrier and has demonstrated neuroprotective effects in multiple neurodegenerative disease models.
Doxycycline additionally disrupts biofilm formation by oral pathogens such as Porphyromonas gingivalis, which has been detected in Alzheimer's brain tissue and whose toxic proteases (gingipains) directly damage neurons. If the Cyrex Alzheimer's LINX panel (Booklet 2) reveals pathogen-associated cross-reactivity — suggesting infectious contributors to neurodegeneration — these medications serve a dual purpose.
Typical dosing: Doxycycline 50–100 mg daily; minocycline 50–100 mg daily. Long-term use requires monitoring for photosensitivity and vestibular effects (minocycline).
A PPAR-gamma agonist originally used for type 2 diabetes, pioglitazone reduces neuroinflammation and improves insulin sensitivity in brain tissue. Some clinical trial data suggest cognitive benefits, particularly in patients with metabolic syndrome or diabetes comorbidity.
Typical dosing: 15–30 mg daily. Monitor for fluid retention and weight gain. Contraindicated in heart failure.
These blood pressure medications have neuroprotective effects beyond their cardiovascular indications. Losartan may reduce amyloid deposition and has anti-inflammatory effects in brain tissue. Telmisartan is particularly interesting because it activates PPAR-gamma (similar to pioglitazone) while also providing vascular protection, and it has superior CNS penetration compared to other ARBs.
Epidemiological studies consistently show that ARB use is associated with lower dementia risk compared to other antihypertensive classes.
Typical dosing: Losartan 25–50 mg daily; telmisartan 40–80 mg daily. These are typically prescribed when blood pressure management is also indicated.
The connection between herpes simplex virus (HSV) and Alzheimer's has gained substantial scientific support. HSV-1 DNA has been found in amyloid plaques, and viral reactivation may trigger neuroinflammation and tau phosphorylation through molecular mimicry. When the Cyrex Alzheimer's LINX panel shows elevated HSV cross-reactivity, antiviral therapy becomes a targeted intervention rather than speculation.
Typical dosing: 500 mg to 1 g twice daily. Well-tolerated for long-term use. Monitor kidney function in older adults.
Supplements play a critical role in a multi-pathway protocol. While no single supplement will reverse Alzheimer's, combinations that target mitochondrial function, protein clearance, neuroinflammation, cerebral blood flow, and membrane integrity work synergistically with prescription interventions.
Nattokinase is a fibrinolytic enzyme derived from fermented soybeans that addresses multiple Alzheimer's pathways simultaneously. It reduces blood viscosity by 15–25%, directly improving cerebral blood flow — a process impaired by 10–15% in mild cognitive impairment and by 40–50% in advanced disease. Critically, nattokinase has been shown to degrade both amyloid fibrils and tau proteins through direct proteolytic activity. It also has anti-inflammatory effects.
Typical dosing: 2,000–4,000 FU daily. Contraindicated with blood thinners or in patients with bleeding disorders.
CoQ10 is an essential electron carrier in the mitochondrial respiratory chain and a powerful lipid-soluble antioxidant. Levels decline significantly with age and are further depleted by statin medications. In Alzheimer's animal models, CoQ10 decreased amyloid pathology and improved behavior. The ubiquinol (reduced) form is better absorbed than ubiquinone.
Typical dosing: 200–400 mg daily of ubiquinol.
PQQ promotes mitochondrial biogenesis — the creation of new mitochondria — by activating PGC-1α, the master regulator of mitochondrial formation. It is neuroprotective against amyloid and alpha-synuclein toxicity. In human trials, 20 mg PQQ combined with 300 mg CoQ10 significantly improved cognitive function in middle-aged and elderly subjects.
PQQ and CoQ10 work synergistically: PQQ creates new mitochondria; CoQ10 ensures they function optimally.
Typical dosing: 10–20 mg daily.
Nicotinamide adenine dinucleotide (NAD+) is essential for mitochondrial function, DNA repair, and sirtuin activation. NAD+ levels decline substantially with age. Supplementation with precursors — nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR) — supports cellular energy production and activates longevity-related sirtuin enzymes.
Typical dosing: NMN 250–500 mg daily or NR 300–600 mg daily.
Acetyl-L-carnitine transports fatty acids into mitochondria for energy production and crosses the blood-brain barrier. Early Alzheimer's studies show modest cognitive benefits, particularly in younger-onset patients.
Typical dosing: 500–2,000 mg daily.
A unique antioxidant functioning in both water-soluble and fat-soluble compartments, alpha-lipoic acid regenerates other antioxidants including vitamin C, vitamin E, and glutathione. It also improves glucose uptake, supporting metabolic treatment. The R-lipoic acid form is preferred for bioavailability.
Typical dosing: 300–600 mg daily of R-lipoic acid.
Curcumin promotes amyloid clearance, modulates microglial activation, and has broad anti-inflammatory effects. Poor bioavailability is the historical limitation — lipophilic formulations (combined with piperine or using phytosome technology) dramatically improve absorption.
Typical dosing: 500–1,000 mg daily of a bioavailable formulation.
Lion's mane is unique among supplements in that it promotes the synthesis of nerve growth factor (NGF) — a neurotrophin essential for neuronal survival and repair. Clinical trials have demonstrated improved cognitive function in older adults with mild cognitive impairment. If the Cyrex panel shows antibodies against NGF or BDNF, lion's mane becomes particularly relevant.
Typical dosing: 1–3 g daily of whole mushroom extract.
AC-11, a water-soluble extract of cat's claw, has demonstrated DNA repair activity and improvements in CD4:CD8 T-cell ratios. In the context of Alzheimer's, it may support immune system function and reduce autoimmune-mediated neurodegeneration. Some evidence suggests direct effects on amyloid clearance.
Typical dosing: 350 mg daily.
A flavonoid antioxidant that inhibits tau aggregation and has senolytic properties — meaning it clears senescent (zombie) cells that produce inflammatory mediators. Quercetin also supports blood-brain barrier integrity.
Typical dosing: 500–1,000 mg daily.
The primary polyphenol in green tea, EGCG inhibits tau aggregation, promotes autophagy, and has anti-inflammatory effects. It also chelates redox-active iron, which contributes to oxidative damage in the Alzheimer's brain.
Typical dosing: 400–800 mg daily. Take on an empty stomach for best absorption.
Berberine activates AMPK, the same metabolic pathway targeted by metformin. It improves insulin sensitivity, reduces neuroinflammation, and has been shown to inhibit cholinesterase activity (similar to standard Alzheimer's medications). For patients who cannot tolerate metformin, berberine provides an alternative approach to metabolic optimization.
Typical dosing: 500 mg two to three times daily.
Omega-3s support blood-brain barrier integrity, reduce neuroinflammation, and are critical structural components of neuronal membranes. EPA (eicosapentaenoic acid) has stronger anti-inflammatory effects, while DHA (docosahexaenoic acid) is the primary structural omega-3 in the brain. Omega-3 fatty acids also support AQP4 (aquaporin-4) function, which is essential for glymphatic clearance.
Typical dosing: 2–4 g daily of combined EPA/DHA from high-quality fish oil or algal sources.
Vitamin D receptors are present throughout the brain, and deficiency is associated with increased Alzheimer's risk. Vitamin D supports immune regulation, reduces neuroinflammation, and may promote amyloid clearance. Many Alzheimer's patients are deficient.
Typical dosing: Dose to achieve and maintain serum 25(OH)D levels of 60–80 ng/mL. Typical supplementation ranges from 2,000–10,000 IU daily depending on baseline levels. Test quarterly until stable.
Fulvic acid supports tight junction repair in both the gut lining and the blood-brain barrier. Given that blood-brain barrier dysfunction is a key mechanism allowing toxins and inflammatory molecules access to brain tissue, restoring barrier integrity is a foundational intervention.
Typical dosing: 250–500 mg fulvic acid daily.
Chromium enhances insulin receptor sensitivity and supports glucose metabolism. In the context of brain insulin resistance — the "type 3 diabetes" component of Alzheimer's — chromium supplementation is a low-risk adjunct to metabolic optimization.
Typical dosing: 200–400 mcg daily as chromium picolinate.
Phosphatidylcholine (PC) is a primary structural component of neuronal membranes. In Alzheimer's disease, there is documented breakdown of membrane phospholipids, and the brain may catabolize its own PC to maintain acetylcholine synthesis — a process sometimes called "autocannibalism." Plaquex delivers purified polyunsaturated phosphatidylcholine intravenously, bypassing gastrointestinal absorption limitations.
The specific molecular species of PC matters. Research by Nishizaki and colleagues demonstrated that DL-PC (dilinoleoyl-phosphatidylcholine) and PO-PC (palmitoyl-oleoyl-phosphatidylcholine) at specific low doses improved cognitive function through PKC signaling pathways involved in synaptic plasticity. The combination at lower doses outperformed higher doses of either alone.
A Cochrane Review (2003) of oral lecithin found no clear clinical benefit, but this used undifferentiated lecithin rather than specific PC species. The composition and route of administration appear to be critical variables.
Administration: IV infusion in a clinical setting. Discuss with your physician.
Plasmalogens are specialized phospholipids abundant in the brain that serve as endogenous antioxidants, are essential for proper vesicle formation and neurotransmitter release, and support membrane integrity. Brain plasmalogen levels are reduced by 40–70% in Alzheimer's disease, and this deficiency may precede clinical symptoms by years.
Dr. Dayan Goodenowe's research through Prodrome Sciences, drawing from large datasets including the Framingham Heart Study, established that low plasmalogen levels correlate strongly with cognitive decline and dementia risk. The ProdromeScan blood test measures plasmalogen levels and other lipid biomarkers, while ProdromeNeuro and ProdromeGlia supplements provide alkylglycerol precursors designed to boost endogenous plasmalogen synthesis.
The clinical evidence for plasmalogen supplementation specifically in Alzheimer's patients is still emerging — small studies and case reports show promise, but large controlled trials are needed. However, the biochemical rationale is compelling: if a structural deficit contributes to pathology, restoring that structure should be therapeutic.
Typical dosing: Per Prodrome Sciences product recommendations. The ProdromeScan test can guide dosing and monitor response.
Noopept (GVS-111) is a peptide-derived nootropic developed in Russia, estimated at approximately 1,000 times more potent than piracetam on a weight basis. It increases expression of both BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) — two neurotrophins critical for neuronal survival, synaptic plasticity, and cognitive function that are impaired in Alzheimer's disease. Noopept also has anti-inflammatory properties and has demonstrated neuroprotective effects in animal models of neurodegeneration.
Typical dosing: 10–30 mg daily, typically divided into two or three doses. Available as a supplement in the United States.
The original nootropic, piracetam improves membrane fluidity (which is reduced in Alzheimer's), enhances mitochondrial function, and modulates neurotransmission. It has been used clinically in Europe for decades for cognitive impairment and has a favorable safety profile at typical doses.
Typical dosing: 1,200–4,800 mg daily in divided doses. Available by prescription in Europe; available as a supplement in some markets.
The Alzheimer's brain has a profound defect in glucose metabolism — it can no longer efficiently use its primary fuel. However, the brain's ability to use ketones as an alternative fuel source remains largely intact even in advanced disease. This metabolic bypass is the rationale for ketogenic interventions.
Dr. Mary Newport documented her husband Steve's remarkable cognitive improvement when she began adding coconut oil to his diet. Steve had been declining rapidly from early-onset Alzheimer's and scored near zero on the clock-drawing test. After beginning coconut oil — and later MCT (medium-chain triglyceride) oil — he showed measurable improvement in cognitive assessments.
The mechanism: coconut oil contains medium-chain fatty acids that the liver converts directly to ketones, providing an alternative energy source for fuel-starved brain cells. MCT oil is more concentrated and produces higher ketone levels.
Typical dosing: MCT oil 20–70 g daily, introduced gradually to minimize gastrointestinal side effects. Start with 1 teaspoon and increase over 2–4 weeks. Coconut oil 2–4 tablespoons daily as a complementary source.
Exogenous ketone supplements (typically beta-hydroxybutyrate salts or esters) provide ketones directly without requiring dietary fat restriction or MCT oil consumption. They produce rapid, measurable increases in blood ketone levels.
Taste has historically been a barrier — ketone esters in particular can be unpleasant. However, newer formulations including ketone salts in flavored powders and capsule forms have substantially improved tolerability. Many patients find that the cognitive benefits outweigh taste concerns, especially when mixed into beverages.
Typical dosing: 10–30 g daily. Monitor with fingerstick ketone meters (target blood BHB 0.5–3.0 mmol/L).
A modified ketogenic diet (approximately 70% fat, 20% protein, 10% carbohydrates) maximizes endogenous ketone production. A full ketogenic diet is not required for benefit — even moderate carbohydrate reduction (100–150 g per day) combined with MCT oil can produce meaningful ketone levels.
A 12–16 hour overnight fast (for example, finishing dinner by 7 PM and not eating breakfast until 7–11 AM) promotes ketone production and activates autophagy — the cellular cleanup process that clears damaged proteins including amyloid and tau. This is one of the simplest interventions with robust mechanistic support.
Note: Fasting protocols must be individualized, particularly for patients with diabetes, low body weight, or those taking medications that affect blood glucose.
HBOT delivers oxygen at greater-than-atmospheric pressure, dramatically increasing dissolved oxygen in plasma. This addresses cerebral hypoperfusion and hypoxia — key features of Alzheimer's pathophysiology that often precede cognitive decline by years.
The mechanistic rationale is multifactorial. HBOT has been shown to increase arteriolar luminal diameter and elevate cerebral blood flow, reduce amyloid burden by shrinking existing plaques and attenuating new plaque formation, activate autophagy-related signaling pathways important for amyloid clearance, and reduce hyperphosphorylated tau aggregation, neuronal degeneration, and neuroinflammation.
Animal studies using AD mouse models demonstrated that early, long-term HBOT intervention slowed AD-like pathology progression — the first evidence that HBOT can alter the disease trajectory. A clinical study from Dalian Medical University with 42 AD and 11 aMCI patients showed cognitive improvement, and the authors proposed HBOT as "a promising alternative therapy." Dr. Paul Harch at LSU reported the first PET scan-documented improvement in brain metabolism in an Alzheimer's patient, describing it as potentially "the first treatment not only to halt, but temporarily reverse disease progression." One case report documented stable cognition over 7 years of HBOT maintenance — maintaining independence and unimpaired driving — versus expected progressive decline.
Typical protocol: 1.5–2.0 ATA, 60-minute sessions, 5 days per week for 8–12 weeks (40–60 sessions). Maintenance protocols may be needed for sustained benefit. Available at hyperbaric oxygen centers. Early intervention appears to produce the greatest benefit.
Molecular hydrogen (H2) acts as a selective antioxidant — it specifically scavenges the most damaging hydroxyl radicals and peroxynitrite while leaving beneficial reactive oxygen species (which serve signaling functions) intact. This selectivity distinguishes it from conventional antioxidants that may interfere with normal cellular signaling.
In Alzheimer's animal models, hydrogen-rich saline reduced neuroinflammation, enhanced autophagy, and improved cognitive performance. A 2023 pilot study in human patients demonstrated cognitive improvement with molecular hydrogen therapy. Administration options include inhalation of hydrogen gas (typically 2–4% hydrogen mixed with air) and hydrogen-rich water (tablets or electrolysis generators). Hydrogen has been used in deep-sea diving for decades with no documented adverse effects even at high concentrations.
Transcranial photobiomodulation uses red (660 nm) and near-infrared (810–850 nm) light to directly stimulate cytochrome c oxidase (Complex IV) in the mitochondrial electron transport chain, increasing ATP production and reducing oxidative stress. This directly addresses the mitochondrial energy crisis that drives Alzheimer's pathology.
Additional effects include reduced oxidative stress and neuroinflammation, improved cerebral blood flow, and potential stimulation of neurogenesis.
Multiple studies have demonstrated cognitive improvements with transcranial photobiomodulation in both healthy aging and early dementia. The intervention is non-invasive and can be administered at home with appropriate devices.
Typical protocol: 10–20 minutes daily using a device delivering appropriate wavelengths (660 nm red; 810–850 nm near-infrared) with sufficient power density. Consistency matters more than session duration.
Neurofeedback uses real-time EEG monitoring to train the brain toward more optimal electrical patterns. The Sens.ai device combines four modalities in a home-based system: EEG-based neurofeedback targeting alpha, theta, and gamma brainwaves; transcranial photobiomodulation via built-in near-infrared LEDs; heart rate variability (HRV) biofeedback for autonomic nervous system optimization; and binaural beat audio entrainment.
Gamma wave training at 40 Hz is particularly relevant to Alzheimer's disease. Gamma synchrony is associated with higher cognitive function and is disrupted early in the disease course. MIT research has demonstrated that 40 Hz light and sound stimulation can reduce amyloid plaques and improve cognitive function in mouse models. The Buck Institute for Research on Aging is collaborating with Sens.ai to study these effects on brain aging in humans.
HRV training addresses the documented decrease in heart rate variability seen in Alzheimer's patients — a marker of autonomic nervous system dysfunction that correlates with disease severity and progression.
Practical considerations: The device costs approximately $1,000 or more with an annual subscription of approximately $300. Results require consistent daily sessions (typically 20–30 minutes). While large Alzheimer's-specific clinical trials are lacking, the individual components each have supporting evidence, and the home-based format eliminates the need for clinic visits.
The MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay) was specifically designed for brain health, combining elements of the Mediterranean and DASH diets. Observational studies have associated strict MIND diet adherence with a 53% reduced risk of Alzheimer's disease, while even moderate adherence showed a 35% risk reduction.
Core principles include emphasizing leafy greens (at least 6 servings per week), berries — especially blueberries and strawberries (at least 2 servings per week), nuts, olive oil as the primary cooking fat, fish (at least once weekly, emphasizing wild-caught fatty fish rich in omega-3s), legumes, and whole grains. Minimize refined carbohydrates, added sugar, processed foods, and industrial seed oils.
The glymphatic system — the brain's waste clearance mechanism — is most active during deep sleep. Cerebrospinal fluid flows through perivascular channels, flushing amyloid-beta, tau, and other metabolic waste products from brain tissue. This process depends on AQP4 (aquaporin-4) channels on astrocytic endfeet, and is dramatically impaired when sleep quality is poor.
Sleep disruption both accelerates Alzheimer's pathology (by reducing clearance) and results from it (as neurodegeneration damages sleep-regulating circuits). Breaking this cycle is essential.
Practical steps: Target 7–8 hours of quality sleep nightly. Evaluate for obstructive sleep apnea (extremely common and undertreated in the elderly — a sleep study is recommended). Maintain consistent sleep and wake times. Minimize blue light exposure in the evening. Keep the bedroom cool (65–68°F). Avoid alcohol, which disrupts deep sleep architecture. Consider melatonin (0.5–3 mg) for sleep onset — melatonin also has direct antioxidant and anti-amyloid properties.
Exercise is one of the most powerful interventions for brain health, supported by extensive evidence. Aerobic exercise increases BDNF (brain-derived neurotrophic factor), which is essential for neuronal survival, synaptic plasticity, and the growth of new neurons in the hippocampus — the memory center most affected in early Alzheimer's. Resistance training improves insulin sensitivity, addressing the metabolic component. Exercise also improves cerebral blood flow, reduces neuroinflammation, enhances glymphatic clearance, and improves sleep quality.
Target: 150 minutes per week of moderate-intensity aerobic activity (brisk walking, cycling, swimming) plus 2–3 sessions of resistance training. Walking is an excellent starting point and can be increased gradually. Consistency matters more than intensity.
The gut-brain axis is a bidirectional communication system linking intestinal health to brain function. In Alzheimer's disease, gut dysbiosis (microbial imbalance) contributes to systemic inflammation, blood-brain barrier disruption, and may directly influence amyloid pathology through bacterial metabolites.
Targeted probiotic supplementation with strains that support the gut-brain axis — particularly Lactobacillus and Bifidobacterium species — can reduce systemic inflammation, improve gut barrier integrity, and produce short-chain fatty acids (butyrate, propionate) that have neuroprotective effects. A randomized controlled trial in Alzheimer's patients demonstrated cognitive improvement with probiotic supplementation compared to placebo.
Prebiotic fibers (inulin, fructo-oligosaccharides, galacto-oligosaccharides) feed beneficial bacteria and promote short-chain fatty acid production. Dietary sources include garlic, onions, asparagus, bananas, and Jerusalem artichokes.
When testing (Booklet 2) reveals specific pathogenic overgrowth or infections — such as Porphyromonas gingivalis (an oral pathogen increasingly linked to Alzheimer's), Helicobacter pylori, or intestinal parasites — targeted antimicrobial treatment addresses a specific inflammatory driver rather than treating blindly.
Herbal antimicrobials with evidence in gut restoration include berberine, oregano oil, and garlic extract. Prescription antimicrobials may be warranted based on testing results.
The interventions in this booklet should be introduced gradually. This allows identification of adverse effects, ensures tolerance, and prevents the overwhelm of starting twenty new interventions simultaneously.
Phase 1 — Foundation (Weeks 1–4): Begin with lifestyle modifications that carry no risk: sleep optimization, dietary changes (MIND diet, time-restricted eating), exercise, and omega-3 supplementation. Start MCT oil at low doses. Begin CoQ10 and PQQ for mitochondrial support. This phase requires no prescriptions and establishes the metabolic foundation.
Phase 2 — Metabolic Optimization (Weeks 4–8): Add metformin or berberine for insulin sensitization. Begin vitamin D optimization (test first). Add nattokinase for cerebral blood flow and protein clearance. Introduce alpha-lipoic acid and NAD+ precursors. If appropriate, begin the ketogenic transition or add exogenous ketones.
Phase 3 — Targeted Prescriptions (Weeks 8–16): Introduce repurposed drugs based on individual test results: sildenafil or tadalafil for cerebral perfusion; LDN for neuroinflammation modulation; valacyclovir if HSV cross-reactivity is elevated; pioglitazone, losartan, or telmisartan based on metabolic and vascular findings. Add curcumin, lion's mane, quercetin, and EGCG. One new prescription at a time, spaced 2–3 weeks apart.
Phase 4 — Advanced Therapies (Weeks 16–24): Begin HBOT if accessible (typically 40–60 sessions over 8–12 weeks). Introduce molecular hydrogen therapy. Start neurofeedback training (Sens.ai or equivalent). Consider Plaquex IV phosphatidylcholine. Add Noopept or piracetam. Begin plasmalogen supplementation if ProdromeScan testing indicates deficiency. Introduce photobiomodulation.
Phase 5 — Gut Restoration (Weeks 12–24, overlapping with Phases 3–4): Implement targeted gut protocol based on testing — probiotics, prebiotics, and antimicrobials as indicated. Address oral health (dental evaluation for periodontal disease, which is linked to P. gingivalis and Alzheimer's risk).
Phase 6 — Maintenance and Monitoring (Ongoing): Continue effective interventions. Repeat cognitive testing (MoCA, CNS Vital Signs) every 3–6 months to track progress. Repeat relevant laboratory testing at 6–12 month intervals. Adjust protocol based on response.
While the evidence for individual interventions is encouraging, significant gaps remain. Most multi-pathway protocols have not been tested in large randomized controlled trials — Bredesen's published work consists of case series rather than blinded, placebo-controlled studies. We know these interventions work individually; we have less data on optimal combinations, sequencing, and dosing when used together.
The sildenafil data, while striking (69% risk reduction in 7.2 million patients), is retrospective — the prospective randomized controlled trial has not yet been completed. The delay reflects the challenge of funding trials for generic drugs, not doubt about the finding.
Plasmalogen supplementation is scientifically compelling but clinically early. HBOT evidence is growing but still based largely on small trials and case reports. Molecular hydrogen therapy showed remarkable results in a pilot study, but replication in larger populations is needed.
Many of the supplements discussed have strong mechanistic rationale and animal data but limited large-scale human trials in Alzheimer's specifically. This is partly because natural products cannot be patented, reducing financial incentive for expensive clinical trials. The absence of large trials should not be confused with absence of effect.
Perhaps the most important unanswered question is timing: how early must intervention begin to achieve reversal rather than merely slowing decline? The evidence consistently suggests that earlier is better — but defining the point of no return remains elusive.
| Category | Intervention | Primary Target | Typical Dosing |
|---|---|---|---|
| Repurposed Drugs | Sildenafil/Tadalafil | Cerebral blood flow, amyloid/tau | 25–50 mg / 5–10 mg daily |
| LDN | Neuroinflammation, microglial modulation | 1.5–4.5 mg at bedtime | |
| Metformin | Insulin resistance, AMPK activation | 500–2,000 mg daily | |
| Intranasal insulin | Brain insulin resistance | 20–40 IU daily | |
| Rapamycin | Autophagy, protein clearance | 1–6 mg weekly (pulsed) | |
| Methylene blue | Mitochondrial function, tau inhibition | 0.5–1 mg/kg daily | |
| Doxycycline | Anti-amyloid, BBB protection | 50–100 mg daily | |
| Minocycline | Microglial modulation | 50–100 mg daily | |
| Pioglitazone | Neuroinflammation, insulin sensitivity | 15–30 mg daily | |
| Losartan/Telmisartan | Vascular protection, anti-amyloid | 25–80 mg daily | |
| Valacyclovir | Viral-driven neurodegeneration | 500 mg–1 g twice daily | |
| Supplements | Nattokinase | Blood viscosity, amyloid/tau clearance | 2,000–4,000 FU daily |
| CoQ10 (ubiquinol) | Mitochondrial function | 200–400 mg daily | |
| PQQ | Mitochondrial biogenesis | 10–20 mg daily | |
| NAD+ precursors (NMN/NR) | Cellular energy, sirtuin activation | 250–500 mg daily | |
| Acetyl-L-carnitine | Mitochondrial fatty acid transport | 500–2,000 mg daily | |
| Alpha-lipoic acid | Antioxidant, glucose metabolism | 300–600 mg daily | |
| Curcumin | Amyloid clearance, anti-inflammatory | 500–1,000 mg daily | |
| Lion's mane | NGF production | 1–3 g daily | |
| AC-11 | DNA repair, immune support | 350 mg daily | |
| Quercetin | Tau inhibition, senolytic | 500–1,000 mg daily | |
| EGCG | Tau inhibition, autophagy | 400–800 mg daily | |
| Berberine | AMPK activation, insulin sensitivity | 500 mg 2–3x daily | |
| Omega-3 (EPA/DHA) | BBB integrity, anti-inflammatory | 2–4 g daily | |
| Vitamin D3 | Immune regulation, neuroprotection | Dose to 60–80 ng/mL | |
| Fulvic acid | BBB and gut barrier repair | 250–500 mg daily | |
| Chromium | Insulin receptor sensitivity | 200–400 mcg daily | |
| Membrane Repair | Plaquex (IV PC) | Membrane integrity, cholinergic support | IV infusion series |
| Plasmalogens | Membrane structure, antioxidant | Per ProdromeScan results | |
| Nootropics | Noopept | BDNF/NGF expression | 10–30 mg daily |
| Piracetam | Membrane fluidity, mitochondria | 1,200–4,800 mg daily | |
| Ketogenic | MCT oil | Alternative brain fuel | 20–70 g daily |
| Exogenous ketones | Direct ketone delivery | 10–30 g daily | |
| Ketogenic diet | Sustained ketosis | 70/20/10 fat/protein/carb | |
| Intermittent fasting | Autophagy, ketone production | 12–16 hour overnight fast | |
| Devices/Therapies | HBOT | Cerebral oxygenation, amyloid clearance | 1.5–2.0 ATA, 40–60 sessions |
| Molecular hydrogen | Selective antioxidant, anti-inflammatory | Inhalation or H2-rich water | |
| Photobiomodulation | Mitochondrial ATP, cerebral blood flow | 10–20 min daily, 660–850 nm | |
| Neurofeedback (Sens.ai) | Gamma synchrony, HRV, photobiomod | 20–30 min daily sessions | |
| Lifestyle | MIND diet | Broad neuroprotection | Ongoing |
| Sleep optimization | Glymphatic clearance | 7–8 hours nightly | |
| Exercise | BDNF, insulin sensitivity, perfusion | 150 min/week + resistance | |
| Gut Health | Probiotics | Gut-brain axis, inflammation | Strain-specific |
| Prebiotics | SCFA production | Dietary + supplemental | |
| Targeted antimicrobials | Pathogen clearance | Based on testing |
Available at Amazon and Barnes & Noble
This booklet is intended for educational purposes only and does not constitute medical advice. Always consult with your physician before starting, stopping, or changing any treatment. The interventions discussed require physician supervision. Do not start, stop, or change any medication or supplement without consulting your healthcare provider.
Version 1.0 — February 2026
© Hippocrates Research Foundation